Lifestream and Polymer resolve patent wrangle:
This article was originally published in Clinica
Executive Summary
Lifestream Technologies has reached a settlement in its patent infringement lawsuit filed against Polymer Technology Systems, a private developer of rapid cholesterol tests. In the agreement, Polymer is to make royalty payments to Lifestream for future sales of products incorporating the latter's HDL (high density lipoprotein) technology, the subject of the dispute. The resolution follows shortly after Lifestream won its appeal to have overturned an initial ruling that found Polymer not guilty of infringement.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.